Anna Ljung

Chief Executive Officer at MOBERG PHARMA AB

Net worth: 986 $ as of 31/03/2024

44 year

76 connections

Health Technology

Distribution Services

Consumer Services

Active connections

Name	Gender	Age	Linked companies	Collaboration
Jørgen Drejer	M	69	SANA AB Saniona A/S Saniona A/S Miscellaneous Commercial ServicesCommercial Services Part of Saniona AB, Saniona A/S is a Danish company dedicated to improving the lives of rare disease patients worldwide through scientific innovation. The private company focuses on Prader-Willi Syndrome, a rare genetic disorder characterized by insatiable appetite, abnormal growth and body composition, low muscle tone, and social/emotional/cognitive deficits. Saniona is a leader in the discovery of highly specific ion channel modulators, which is a validated approach to treating diseases such as diabetes, hypertension, and epilepsy. The company's robust ion channel drug discovery engine has led to the development of San711, a first-in-class positive allosteric modulator of GABAA ?3 receptors, and San903, a potential first-in-class inhibitor of the calcium-activated potassium ion channel, KCA3.1, both of which are in development for rare neuropathic, inflammatory, and fibrotic disorders.	13 years
Joseph deBethizy	M	74	SANA AB Saniona A/S Saniona A/S Miscellaneous Commercial ServicesCommercial Services Part of Saniona AB, Saniona A/S is a Danish company dedicated to improving the lives of rare disease patients worldwide through scientific innovation. The private company focuses on Prader-Willi Syndrome, a rare genetic disorder characterized by insatiable appetite, abnormal growth and body composition, low muscle tone, and social/emotional/cognitive deficits. Saniona is a leader in the discovery of highly specific ion channel modulators, which is a validated approach to treating diseases such as diabetes, hypertension, and epilepsy. The company's robust ion channel drug discovery engine has led to the development of San711, a first-in-class positive allosteric modulator of GABAA ?3 receptors, and San903, a potential first-in-class inhibitor of the calcium-activated potassium ion channel, KCA3.1, both of which are in development for rare neuropathic, inflammatory, and fibrotic disorders.	5 years
Thomas Feldthus	M	64	SANA AB Saniona A/S Saniona A/S Miscellaneous Commercial ServicesCommercial Services Part of Saniona AB, Saniona A/S is a Danish company dedicated to improving the lives of rare disease patients worldwide through scientific innovation. The private company focuses on Prader-Willi Syndrome, a rare genetic disorder characterized by insatiable appetite, abnormal growth and body composition, low muscle tone, and social/emotional/cognitive deficits. Saniona is a leader in the discovery of highly specific ion channel modulators, which is a validated approach to treating diseases such as diabetes, hypertension, and epilepsy. The company's robust ion channel drug discovery engine has led to the development of San711, a first-in-class positive allosteric modulator of GABAA ?3 receptors, and San903, a potential first-in-class inhibitor of the calcium-activated potassium ion channel, KCA3.1, both of which are in development for rare neuropathic, inflammatory, and fibrotic disorders.	13 years
Rikard Akhtarzand	M	52	ADDVISE GROUP AB	16 years
Carl Johan Bertil Sundberg	M	66	SANA AB Saniona A/S Saniona A/S Miscellaneous Commercial ServicesCommercial Services Part of Saniona AB, Saniona A/S is a Danish company dedicated to improving the lives of rare disease patients worldwide through scientific innovation. The private company focuses on Prader-Willi Syndrome, a rare genetic disorder characterized by insatiable appetite, abnormal growth and body composition, low muscle tone, and social/emotional/cognitive deficits. Saniona is a leader in the discovery of highly specific ion channel modulators, which is a validated approach to treating diseases such as diabetes, hypertension, and epilepsy. The company's robust ion channel drug discovery engine has led to the development of San711, a first-in-class positive allosteric modulator of GABAA ?3 receptors, and San903, a potential first-in-class inhibitor of the calcium-activated potassium ion channel, KCA3.1, both of which are in development for rare neuropathic, inflammatory, and fibrotic disorders.	9 years
Palle Christophersen	M	66	SANA AB Saniona A/S Saniona A/S Miscellaneous Commercial ServicesCommercial Services Part of Saniona AB, Saniona A/S is a Danish company dedicated to improving the lives of rare disease patients worldwide through scientific innovation. The private company focuses on Prader-Willi Syndrome, a rare genetic disorder characterized by insatiable appetite, abnormal growth and body composition, low muscle tone, and social/emotional/cognitive deficits. Saniona is a leader in the discovery of highly specific ion channel modulators, which is a validated approach to treating diseases such as diabetes, hypertension, and epilepsy. The company's robust ion channel drug discovery engine has led to the development of San711, a first-in-class positive allosteric modulator of GABAA ?3 receptors, and San903, a potential first-in-class inhibitor of the calcium-activated potassium ion channel, KCA3.1, both of which are in development for rare neuropathic, inflammatory, and fibrotic disorders.	13 years
Anita Milland	F	56	SANA AB	10 years
Pierandrea Muglia	M	58	SANA AB	1 years
Nikolaj Sørensen	M	52	MOBERG PHARMA AB	3 years
Erik Staffan Torstensson	M	52	ADDVISE GROUP AB	4 years
Anders Lundmark	M	66	MOBERG PHARMA AB	2 years
Lars Fredrik Celsing	M	57	ADDVISE GROUP AB	8 years
Markus Jerling	M	72	ONCOZENGE AB	3 years
Håkan Wallin	M	62	MOBERG PHARMA AB	1 years
Karin Nielsen	F	54	SANA AB	-
Kerstin Valinder-Strinnholm	F	64	MOBERG PHARMA AB	2 years
Gunilla Wengström	F	62	MOBERG PHARMA AB	5 years
Anders Bröijersén	M	60	MOBERG PHARMA AB	1 years
Hanna Rebecca Lovisa Myhrman	F	32	ADDVISE GROUP AB	5 years
Mark Beveridge	M	46	MOBERG PHARMA AB	9 years
Anker Gunvald Lundemose	M	63	Saniona A/S Saniona A/S Miscellaneous Commercial ServicesCommercial Services Part of Saniona AB, Saniona A/S is a Danish company dedicated to improving the lives of rare disease patients worldwide through scientific innovation. The private company focuses on Prader-Willi Syndrome, a rare genetic disorder characterized by insatiable appetite, abnormal growth and body composition, low muscle tone, and social/emotional/cognitive deficits. Saniona is a leader in the discovery of highly specific ion channel modulators, which is a validated approach to treating diseases such as diabetes, hypertension, and epilepsy. The company's robust ion channel drug discovery engine has led to the development of San711, a first-in-class positive allosteric modulator of GABAA ?3 receptors, and San903, a potential first-in-class inhibitor of the calcium-activated potassium ion channel, KCA3.1, both of which are in development for rare neuropathic, inflammatory, and fibrotic disorders.	-
Annica Magnusson	F	61	MOBERG PHARMA AB	5 years
Johanne Louise Brændgaard	F	50	ADDVISE GROUP AB	3 years
Leif Jan Eugen Andersson	M	67	Saniona A/S Saniona A/S Miscellaneous Commercial ServicesCommercial Services Part of Saniona AB, Saniona A/S is a Danish company dedicated to improving the lives of rare disease patients worldwide through scientific innovation. The private company focuses on Prader-Willi Syndrome, a rare genetic disorder characterized by insatiable appetite, abnormal growth and body composition, low muscle tone, and social/emotional/cognitive deficits. Saniona is a leader in the discovery of highly specific ion channel modulators, which is a validated approach to treating diseases such as diabetes, hypertension, and epilepsy. The company's robust ion channel drug discovery engine has led to the development of San711, a first-in-class positive allosteric modulator of GABAA ?3 receptors, and San903, a potential first-in-class inhibitor of the calcium-activated potassium ion channel, KCA3.1, both of which are in development for rare neuropathic, inflammatory, and fibrotic disorders.	-
Janus Schreiber Larsen	M	52	SANA AB	-
Fredrik Mella	M	54	ADDVISE GROUP AB	2 years
Rudolf Baumgartner	M	65	SANA AB	4 years
Oliver Humlen	M	33	ADDVISE GROUP AB	1 years

Connections Chart

Multi-company connection

Former connections

Name	Gender	Age	Linked companies	Collaboration
Peter Gunnar Maurits Wolpert	M	55	MOBERG PHARMA AB	16 years
Thomas Lennart Eklund	M	57	MOBERG PHARMA AB	4 years
Karl Fredrik Otto Granström	M	56	MOBERG PHARMA AB	16 years
Erland Pontusson	M	71	ADDVISE GROUP AB	9 years
Mattias Klintemar	M	57	ONCOZENGE AB MOBERG PHARMA AB	-
Mats Gunnar Pettersson	M	78	MOBERG PHARMA AB	6 years
Gustaf Bertel Lindewald	M	82	MOBERG PHARMA AB	-
Torbjörn Wärnheim	M	66	MOBERG PHARMA AB	7 years
Rami Levin	M	55	SANA AB	2 years
Cindy Wong	M	65	MOBERG PHARMA AB ONCOZENGE AB	3 years
Thomas Bjerregaard Thomsen	M	54	MOBERG PHARMA AB	4 years
Geert Cauwenbergh	M	70	MOBERG PHARMA AB	7 years
Pirkko Sulila Tamsen	M	65	ONCOZENGE AB	3 years
Torbjörn Mattias Koivisto	M	55	MOBERG PHARMA AB	9 years
Robert Hoffman	M	58	SANA AB	1 years
Wenche Nelly A. Rolfsen Sandsborg	M	72	MOBERG PHARMA AB	7 years
Andrew B. Hochman	M	57	MOBERG PHARMA AB	-
Fredrik Netzel	M	55	MOBERG PHARMA AB	8 years
Torben Mogensen	M	71	ONCOZENGE AB	3 years
Kyle Haraldsen	M	-	SANA AB	-
Linea Aspesi	F	-	SANA AB	-
Sebastian Robson	M	38	ADDVISE GROUP AB	1 years
Jesper Lind	M	64	MOBERG PHARMA AB	-
Edward Saltzman	M	69	SANA AB	3 years
Sarah Hellerfelt	F	42	MOBERG PHARMA AB	2 years
Anna Yvonne Monica Malm Bernsten	F	63	MOBERG PHARMA AB	1 years
Wendy Dwyer	F	50	SANA AB	1 years
Shaw Sorooshian	M	60	MOBERG PHARMA AB	2 years
Bengt Miller	M	-	ADDVISE GROUP AB	1 years
Ingela Berglund	F	-	MOBERG PHARMA AB	-
Denelle Waynick	F	57	SANA AB	-
Kjell Rensfeldt	M	67	MOBERG PHARMA AB	11 years
Marie Scherlund	M	58	MOBERG PHARMA AB	-
Bengt Åke Ingemar Aldén	M	81	MOBERG PHARMA AB	-
Magnus Persson	M	60	MOBERG PHARMA AB	-
George Aitken-Davies	M	46	MOBERG PHARMA AB	2 years
Peter Michael Rothschild	M	74	MOBERG PHARMA AB	-
Hilde Furberg	F	65	ONCOZENGE AB	3 years
Sara Catherine Brandt	F	61	MOBERG PHARMA AB	2 years
Trista Morrison	F	-	SANA AB	-
Martin Ingman	M	62	MOBERG PHARMA AB	9 years
Jason Amello	M	55	SANA AB	2 years
Lena Pereswetoff Morath	M	64	MOBERG PHARMA AB	-
Jeff Vernimb	M	61	MOBERG PHARMA AB	2 years
Paul de Potocki	M	62	ONCOZENGE AB	2 years
Marie Moberg	F	-	MOBERG PHARMA AB	-
Ernst Åke Bertil Karlmark	M	86	MOBERG PHARMA AB	6 years
Agneta Larhed	M	60	MOBERG PHARMA AB	-

Statistics

Country	Connections	% of total
United States	40	52.63%
Denmark	21	27.63%
Sweden	17	22.37%

Age of Connections

Active

Past

Male

Female

Members of the board

Executives

Origin of connections